Hyperkalemia

Spironolactone Helps HF Patients With CKD, But Ups Hyperkalemia Risk

Spironolactone Helps HF Patients With CKD, But Ups Hyperkalemia Risk

Spironolactone improved cardiovascular outcomes in heart failure patients with chronic kidney disease, but increased their risk of hyperkalemia.

Hyperkalemia Increases Risk for Progression to ESRD

Hyperkalemia Increases Risk for Progression to ESRD

Elevated serum potassium levels increased the risk for end-stage renal disease by approximately 30%, independent of decline in estimated glomerular filtration rate.

Dyskalemia Common in Heart Failure

Dyskalemia Common in Heart Failure

Sex, high and low baseline potassium levels, and reduced renal function independently predict hyper- and hypokalemia in patients with heart failure.

Hyperkalemia Drug May Act as Phosphate Binder

Hyperkalemia Drug May Act as Phosphate Binder

In a study, patiromer lowered serum phosphate in patients with hyperkalemia and hyperphosphatemia.

Patiromer Effectiveness in Hyperkalemia Unaffected by RAASi Use

Patiromer Effectiveness in Hyperkalemia Unaffected by RAASi Use

Patiromer's potassium-lowering effect in patients with hyperkalemia is similar regardless of whether or not they are taking renin-angiotensin-aldosterone system inhibitors

Safe Potassium Range May Vary by CKD Stage

Safe Potassium Range May Vary by CKD Stage

Study suggests the optimal range is 3.36 to 5.18 mmol/L in CKD stage 3 and 3.26 to 5.53 mmol/L in CKD stages 4 to 5.

Single-Dose Potassium-Lowering Drug Effective in CKD, ESRD

Single-Dose Potassium-Lowering Drug Effective in CKD, ESRD

A single 30-gram oral dose of sodium polystyrene sulfonate resulted in a significant decrease in serum potassium within 24 hours.

Studies Provide Detailed Look at Treatment-Related Hyperkalemia

Studies Provide Detailed Look at Treatment-Related Hyperkalemia

Rates of hyperkalemia associated with receipt of renin-angiotensin-aldosterone system inhibitors vary by age and comorbidities.

Hyperkalemia Common in Stages 2-5 CKD

Hyperkalemia Common in Stages 2-5 CKD

Longitudinal study with preplanned serum potassium measurements may provide a more accurate estimate of the burden of hyperkalemia among CKD patients.

Hyperkalemia Drug Receives FDA Approval

Hyperkalemia Drug Receives FDA Approval

Sodium zirconium cyclosilicate exchanges potassium for sodium and hydrogen throughout the gastrointestinal tract.

Newsletter Signup